Gregory Norden Net Worth

The estimated Net Worth of Gregory Norden is at least $18.5 Million dollars as of 6 May 2024. Mr. Norden owns over 41,133 units of Zoetis Inc stock worth over $16,823,994 and over the last 12 years he sold ZTS stock worth over $1,360,615. In addition, he makes $355,000 as Independent Director at Zoetis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Norden ZTS stock SEC Form 4 insiders trading

Gregory has made over 17 trades of the Zoetis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 41,133 units of ZTS stock worth $7,814,859 on 6 May 2024.

The largest trade he's ever made was exercising 41,133 units of Zoetis Inc stock on 6 May 2024 worth over $7,814,859. On average, Gregory trades about 2,170 units every 68 days since 2013. As of 6 May 2024 he still owns at least 88,552 units of Zoetis Inc stock.

You can see the complete history of Mr. Norden stock trades at the bottom of the page.

Gregory Norden biography

Gregory Norden is Independent Director of the Company. Prior to his role as Chief Financial Officer of Wyeth, Mr. Norden held various senior positions with Wyeth Pharmaceuticals and American Home Products. Prior to his affiliation with Wyeth, Mr. Norden served as Audit Manager at Arthur Andersen & Co. Mr. Norden currently serves on the boards of Entasis Therapeutics, a leader in the discovery and development of breakthrough anti-infective products; NanoString Technologies, a provider of life science tools for translational research and development of molecular diagnostic products; Royalty Pharma, a leader in the acquisition of revenue-producing intellectual property; and Univision, the leading media company serving Hispanic America. Mr. Norden is a former director of Welch Allyn, where he served until 2015; Lumara Health, where he served until 2014; and Human Genome Sciences, Inc., where he served until 2012. In addition, Mr. Norden is the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory services. Mr. Norden’s background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, along with his public company board experience, make him a valuable member of our Board.

What is the salary of Gregory Norden?

As the Independent Director of Zoetis Inc, the total compensation of Gregory Norden at Zoetis Inc is $355,000. There are 8 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.

How old is Gregory Norden?

Gregory Norden is 62, he's been the Independent Director of Zoetis Inc since 2013. There are 7 older and 15 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.

What's Gregory Norden's mailing address?

Gregory's mailing address filed with the SEC is C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK, NY, 10022.

Insiders trading at Zoetis Inc

Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio, and Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.

What does Zoetis Inc do?

Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.

Complete history of Mr. Norden stock trades at Nanostring Technologies Inc, Royalty Pharma plc, Zoetis Inc, Entasis Therapeutics Inc, and Praxis Precision Medicines

Zoetis Inc executives and stock owners

Zoetis Inc executives and other stock owners filed with the SEC include:

• Glenn David,
  Chief Financial Officer, Executive Vice President
• Kristin Peck,
  Chief Executive Officer, Director
• Catherine Knupp,
  Executive Vice President, President - Research and Development
• Kristin C. Peck,
  CEO & Director
• Wafaa Mamilli,
  Exec. VP and Chief Information & Digital Officer
• Roman Trawicki,
  Exec. VP and Pres of Global Manufacturing & Supply
• Glenn C. David,
  Exec. VP and Group Pres of International Operations, Aquaculture, BioDevices & Pet Insurance
• Michael McCallister,
  Non-Executive Independent Chairman of the Board
• Robert Scully,
  Independent Director
• Gregory Norden,
  Independent Director
• Paul Bisaro,
  Independent Director
• William Steere,
  Independent Director
• Linda Rhodes,
  Independent Director
• Willie Reed,
  Independent Director
• Louise Parent,
  Independent Director
• Sanjay Khosla,
  Independent Director
• Frank D'Amelio,
  Independent Director
• Roman Trawicki,
  Executive Vice President, President - Global Manufacturing and Supply
• Heidi Chen,
  Executive Vice President, General Counsel, Corporate Secretary
• Roxanne Lagano,
  Chief Human Resource Officer, Executive Vice President and Global Operations
• Heidi C. Chen,
  Exec. VP, Gen. Counsel, Corp. Sec. & Bus. Lead of Human Health Diagnostics
• Roxanne Lagano,
  Exec. VP and Chief HR Officer & Global Operations
• Wetteny N. Joseph,
  Exec. VP & CFO
• Timothy J. Bettington,
  Exec. VP and Pres of U.S. Operations & Global Customer Experience
• William Price,
  VP & Chief Communications Officer
• Steven Frank,
  VP of Investor Relations
• Gavin Hattersley,
  Director
• Robert Edward Kelly,
  Executive Vice President
• Alejandro Bernal,
  Executive Vice President
• Juan Ramon Alaix,
  Director
• Clinton A. Jr. Lewis,
  Executive Vice President
• Sherry N Pudloski,
  Executive Vice President
• Robert J Polzer,
  Executive Vice President
• Amy W Schulman,
  Director
• Sandra J. Beaty,
  Executive Vice President
• Joyce J. Lee,
  Executive Vice President
• Douglas E. Giordano,
  Director
• William F Doyle,
  
• Inc Pfizer,
  Director
• Square Capital Management, ...,
  
• Stefan Weiskopf,
  Executive Vice President
• Richard A. Passov,
  EVP, Chief Financial Officer
• Paul Herendeen,
  Exec. V.P. and CFO
• Charles H Hill,
  Director
• Geno J Germano,
  Director
• Andrew Fenton,
  Executive Vice President
• James Michael Mc Farland,
  Executive Vice President
• Wafaa Mamilli,
  Executive Vice President
• Timothy J Bettington,
  Executive Vice President
• Antoinette Renee Leatherberry,
  Director
• Astorga Jeannette Ferran,
  Executive Vice President
• Abhay U Nayak,
  Executive Vice President
• Wetteny Joseph,
  Chief Financial Officer
• Rimma Driscoll,
  Executive Vice President
• Vanessa Broadhurst,
  Director
• Jamie Brannan,
  Executive Vice President
• Nicholas Ashton,
  Executive Vice President
• Soria Ester Banque,
  Executive Vice President